Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results.

@article{Trefzer2005TumourdendriticHC,
  title={Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results.},
  author={Uwe Trefzer and Gunda Herberth and Karolina Wohlan and Annett Milling and Max Thiemann and Tumenjargal Sharav and Katrin Sparbier and Wolfram Sterry and Peter Walden},
  journal={Vaccine},
  year={2005},
  volume={23 17-18},
  pages={
          2367-73
        }
}
  • Uwe Trefzer, Gunda Herberth, +6 authors Peter Walden
  • Published in Vaccine 2005
  • Medicine
  • Hybrid cell vaccines of autologous tumour cells fused with allogenic dendritic cells (DC) combine the tumour's antigenicity with the immune-stimulatory capacity of mature dendritic cells and allogenic MHC class II molecules to activate T cell help and induce tumour-specific cytotoxic T cells. This concept was tested in a clinical trial with melanoma stage III and IV patients. Seventeen patients were evaluated: one experienced complete, one partial response and six stable disease with long… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 38 CITATIONS